FDA
-
-
-
-
-
-
-
BioInvent (BIVN) Announces IND Approved by FDA for Phase I/IIa Trial of Anti-TNFR2 Antibody BI-1808
-
-
-
-
-
-
-
BioInvent Interim Report January 1 - March 31, 2019
-
-
323,752 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

